Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy
Authors:
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Neuromuscular Disorders
- Vol. 31 (9) , 803-813
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The Pathogenesis and Therapy of Muscular DystrophiesAnnual Review of Genomics and Human Genetics, 2015
- Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapyDisease Models & Mechanisms, 2015
- An overview of current and emerging SERMsThe Journal of Steroid Biochemistry and Molecular Biology, 2014
- Biomarkers and surrogate endpoints in Duchenne: Meeting reportNeuromuscular Disorders, 2014
- Pharmacological prospects in the treatment of Duchenne muscular dystrophyCurrent Opinion in Neurology, 2013
- THE 6‐minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter studyMuscle & Nerve, 2013
- The Anticancer Drug Tamoxifen Counteracts the Pathology in a Mouse Model of Duchenne Muscular DystrophyThe American Journal of Pathology, 2013
- The Use of Tamoxifen to Improve Height Potential in Short Pubertal BoysPediatrics, 2005
- Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastiaThe Journal of Pediatrics, 2004
- Tamoxifen in Postmenopausal WomenDrugs & Aging, 1996